Paris (France), April 27, 2020 – 7.00 p.m. CEST - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo”, “the Company” or “the Group”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2019 Universal Registration Document for the year ended December 31, 2019.

The document, filed with the French stock-market authority (Autorité des Marchés Financiers) on April 27, 2020, is available to the public free of charge upon request, as per current legal regulations, on the Company’s website https://www.onxeo.com/investors-en/investors/registration-documents as well as on that of the AMF (www.amf-france.org).

The 2019 annual financial report, the report on corporate governance, the required information in relation to the share repurchase program, as well as the auditors’ reports and information on the fees paid to the statutory auditors in 2019 are included in this Universal Registration Document.

• Access the press release in .pdf format